[Federal Register Volume 61, Number 243 (Tuesday, December 17, 1996)]
[Notices]
[Pages 66288-66289]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-31883]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESS: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
4'- and 4',4''-Substituted-3(diphenylmethoxy)tropane
Analogs As Cocaine Therapeutics
AH Newman, AC Allen, RH Kline, S. Izenwasser, JL Katz (NIDA)
Serial No. 08/667,024 filed 20 Jun 96 (claiming benefit of 60/000,378
filed 21 Jun 95)
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext. 223
The invention provides a series of 4'- and 4',4''-substituted
benztropine analogs that demonstrate high affinity binding (K1<30
nM) to the dopamine transporter and bind selectively (>100-fold) over
the other monoamine transporters. These compounds block dopamine
reuptake in vitro and yet do not demonstrate a cocaine-like behavioral
profile in animal models of psychomotor stimulant abuse. Structure-
Activity Relationships suggest that these compounds interact at a
binding domain that differs from that of cocaine at the dopamine
transporter. The invention also describes cocaine analogs comprising N-
substituted 2',3' and 3',3'' and 3',4''-analogs, which exhibit a
cocaine-like behavioral profile. One of the compounds exhibits cocaine-
like activity and anti-muscarinic receptor activity, which may improve
its therapeutic utility. These compounds represent an unprecedented
class of dopamine uptake inhibitors that may have potential as cocaine-
abuse therapeutics, since they have neurochemical similarities to
cocaine and yet do not appear to have abuse liability. Further,
radiolabeled analogs will be suitable for imaging the dopamine
transporter in mammalian brain using SPECT and PET and thus would be
useful in the diagnoses and monitoring of neurodegenerative disorders
involving the dopaminergic system (e.g., Parkinson's disease). In
addition, the invention provides pharmaceutical compositions comprising
an analog of the invention and a pharmaceutically acceptable carrier
excipient. (portfolios: Central Nervous System--Therapeutics,
psychotherapeutics, drug dependence; Central Nervous System--
Therapeutics, neurological, antiparkinsonian; Central Nervous System--
Diagnostics, in vivo)
Conjugate Vaccine For Nontypeable Haemophilus Influenzae
X-X Gu (NIDCD), C-M Tsai (CBER), DJ Lim (NIDCD), JB Robbins (NICHD)
Serial No. 60/016,020 filed 23 Apr 96
Licensing Contact: Elaine Gese, 301/496-7056 ext. 282
[[Page 66289]]
This invention is a vaccine for the prevention of disease caused by
nontypeable H. influenzae, which causes 25-40% of otitis media cases
(middle ear infections) in children and other respiratory tract
diseases in humans. The emergence of antibiotic-resistant bacteria has
caused concern that treatment of otitis media will become more
problematic. This invention offers a new approach to managing otitis
media. The vaccine is composed of lipooligosaccharide, isolated from
the surface of strains of nontypeable H. influenzae and treated with
hydrazine to remove esterified fatty acids, covalently conjugated to an
immunogenci carrier, such as tetanus toxoid. The conjugates have been
shown to be nontoxic by the limulus amebocyte assay, rabbit pyrogen
test, and in a mouse lethal toxicity test. Antisera raised in rabbits
immunized with the conjugate is bactericidal. (portfolio: Infectious
Diseases--Vaccines, bacterial)
Materials And Methods for Detection and Treatment of Insulin Dependent
Diabetes
NK Maclaren, AL Notkins, Q Li, MS Lan (NIDR)
Serial No. 08/514,213 filed 11 Aug 95 and
Serial No. 08/548,159 filed 25 Oct 95
Licensing Contact: J. Peter Kim, 301/496-7056 ext. 264
Insulin-dependent diabetes mellitus (IDDM) affects close to one
million people in the United States. It is an autoimmune disease in
which the immune system produces antibodies that attack the body's own
insulin-manufacturing cells in the pancreas. Patients require daily
injections of insulin to regulate blood sugar levels. The invention
identified two proteins, named IA-2 and IA-2, that are
important markers for type I (juvenile, insulin-dependent) diabetes.
IA-2/IA-2, when used in diagnostic tests, recognized
autoantibodies in 70 percent of IDDM patients. Combining IA-2/IA-
2 with other known markers increased the level of
identification to 90 percent of individuals with IDDM. Moreover, the
presence of autoantibodies to IA-2/IA-2 in otherwise normal
individuals was highly predictive in identifying those at risk of
ultimately developing clinical disease. It is now possible to develop a
rapid and effective test that can screen large populations for IDDM. In
addition, IA-2/IA-2 are candidates for immune tolerance and
prevention of disease development.
Compositions Comprising Vitamin F
C Weinberger, S Kitareewan (NIEHS)
Serial No. 60/003,443 filed 08 Sep 95; PCT/US96/15205 filed 06 Sep 96
Licensing Contact: Carol Lavrich, 301/496-7056 ext. 287
This invention relates to a collection of potential fat-soluble
vitamins that may coordinate animal metabolism and development. RXR is
a nuclear receptor that plays a central role in cell signaling by
heterodimerizing with receptors binding thyroid hormones, retinoids and
vitamin D. The invention and others of its compositions can be
characterized as likely physiological effectors that may represent
essential components for human nutrition and cell growth. Thus, the
invention suggests that it may coordinate cell physiology through RXR-
dependent hormone signaling pathways.
Macrocyclic Chelates, And Methods of Use Thereof
OA Gansow, K Kumar (NCI)
Serial No. 08/140,714 filed 22 Oct 93
U.S. Patent 5,428,154 issued 27 Jul 95
Licensing Contact: Raphe Kantor, 301/496-7735 ext. 247
Substituted 1,4,7,10-tetraaza cyclododecane-N,N', N'', N'''-
tetraacetic acid (DOTA) has numerous desirable chelating qualities that
make it useful for treating a number of cdellular disorders. Presently
available chelating agents lack specificity for their intended targets
or do not adequately bind the chelated metal ion. These substituted
DOTAs have a strong affinity for a number of metal ions. They can also
be linked to biomolecules to form systems for delivering the chelated
metal ion, which can be radiolabeled, to specific sites within a cell
or organelle. (portfolio: Cancer--Therapeutics, immunoconjugates,
conjugate chemistry)
The Cloning of Perilipin Proteins
C Londos, AS Greenberg, AR Kimmel, JJ Egan (NIDDK)
Serial No. 08/132,649 filed 04 Oct 93
U.S. Patent 5,585,462 to issue 17 Dec 96
Licensing Contact: Ken Hemby, 301/496/7735 ext. 265
Perilipins are found at the surface of lipid storage droplets of
adipocytes. Little is known about the molecules on the surface of lipid
droplets that may be involved in lipid metabolism and trafficking. The
present invention provides isolated nucleic acid sequences which encode
a family of perilipin proteins as well as isolated, purified perilipin
proteins. These are useful as markers for differentiation of true
adipocyte cells from non-adipocyte cells which, as a result of
pathophysiological conditions, assume adipocyte characteristics.
(portfolio: Cancer--Research Materials)
Dated: December 6, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-31883 Filed 12-16-96; 8:45 am]
BILLING CODE 4140-01-M